Retipharma_HighRes

RetiPharma, a Copenhagen, Denmark-based company developing products for the treatment of degenerative eye disorders based on an in vivo platform for translation from in vivo models to humans, secured EUR 1.3m as funding in a convertible note which paid in tranches according to achievement of agreed milestones.